CSRxP Statement on Potential Big Pharma Bailout

“Only Big Pharma would use bipartisan opioid legislation as another opportunity to make money off the very crisis they themselves created. The focus of this effort […]

Read more

CSRxP Urges House Members To Maintain Transparency Provision In Senate-Passed Appropriations Bill

CSRxP-Supported Policy Enables HHS To Require Drug Price Disclosure In Direct-To-Consumer Advertising Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) sent a letter urging […]

Read more

CSRxP Applauds Senate Action To Boost Drug Price Transparency For Consumers

Legislation Includes CSRxP-Supported Amendment Enabling HHS To Require Disclosure of Drug Prices in Direct-to-Consumer Advertising   The Campaign for Sustainable Rx Pricing issued the following statement […]

Read more

Statement on Celgene’s Revlimid Price Hike

CSRxP spokesman Will Holley released the following statement in response to today’s report that Celgene will once again raise the price of Revlimid: “Today’s announcement that […]

Read more